Matthew E. Butchbach, Ph.D.
Affiliations: | 2003 | Ohio State University, Columbus, Columbus, OH |
Area:
Biochemistry, Neuroscience Biology, Molecular Biology, Cell BiologyGoogle:
"Matthew Butchbach"Mean distance: 35622
Parents
Sign in to add mentorChien-liang G. Lin | grad student | 2003 | Ohio State | |
(Regulation of glutamate transport by GTRAP3-18 and by lipid rafts.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Edwards JD, Butchbach ME. (2016) Effect of the Butyrate Prodrug Pivaloyloxymethyl Butyrate (AN9) on a Mouse Model for Spinal Muscular Atrophy. Journal of Neuromuscular Diseases. 3: 511-515 |
Rossi SL, Lumpkin CJ, Harris AW, et al. (2016) Identification of early gene expression changes in primary cultured neurons treated with topoisomerase I poisons. Biochemical and Biophysical Research Communications |
Butchbach ME, Lumpkin CJ, Harris AW, et al. (2016) Protective effects of butyrate-based compounds on a mouse model for spinal muscular atrophy. Experimental Neurology |
Harris AW, Butchbach ME. (2015) The effect of the DcpS inhibitor D156844 on the protective action of follistatin in mice with spinal muscular atrophy. Neuromuscular Disorders : Nmd. 25: 699-705 |
Mack SG, Cook DJ, Dhurjati P, et al. (2014) Systems biology investigation of cAMP modulation to increase SMN levels for the treatment of spinal muscular atrophy. Plos One. 9: e115473 |
Maeda M, Harris AW, Kingham BF, et al. (2014) Transcriptome profiling of spinal muscular atrophy motor neurons derived from mouse embryonic stem cells. Plos One. 9: e106818 |
Butchbach ME, Singh J, Thorsteinsdóttir M, et al. (2010) Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy. Human Molecular Genetics. 19: 454-67 |
Mattis VB, Butchbach ME, Lorson CL. (2008) Detection of human survival motor neuron (SMN) protein in mice containing the SMN2 transgene: applicability to preclinical therapy development for spinal muscular atrophy. Journal of Neuroscience Methods. 175: 36-43 |
Thurmond J, Butchbach ME, Palomo M, et al. (2008) Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy. Journal of Medicinal Chemistry. 51: 449-69 |
Gabanella F, Butchbach ME, Saieva L, et al. (2007) Ribonucleoprotein assembly defects correlate with spinal muscular atrophy severity and preferentially affect a subset of spliceosomal snRNPs. Plos One. 2: e921 |